ATLANTA, Jan. 4 /PRNewswire/ -- According to data compiled in the just-
released NanoBiotech News 2006 Nanomedicine, Device & Diagnostic Report, 130
nanotech-based drugs and delivery systems and 125 devices or diagnostic tests
have entered preclinical, clinical, or commercial development, meaning the
clinical pipeline has grown 68% since last year at this time.
NanoBiotech News 2006 Nanomedicine, Device & Diagnostic Report, produced
by the publishers of NanoBiotech News, includes the associated company or
academic research center name, product name, type, indication and status for
each of the 255 entries. Additionally, key experts provide in-depth analysis
of the state of the industry and the products currently under development.
This executive briefing is the only resource to compile a comprehensive status
report of all nano-based drugs and medical devices, providing a remarkable
look at the market's quickening pulse.
"What we're seeing is a growing community of nanobiotech drug and device
developers who are digging in their heels -- and surviving," says Lynn Yoffee,
associate publisher of NanoBiotech News, which produced the 2006 Nanomedicine,
Device & Diagnostic Report. "Along with that comes the advance of numerous
product candidates marching beyond concept well into trials, ever closer to
market. The industry is experiencing an evolution similar to what we saw in
biotechnology, but the nanobiotech developers are putting together therapies
and diagnostics with an even more astonishing 'wow' factor." Some of those
promising products include:
* A nanoviricide for Avian flu
* Nano-based coatings for medical implants that will permit safe magnetic
* A multifunctional nano device that selectively binds to cancer tumor
cells and destroys them
"Although we keep a very close eye on the progress of drug candidates, we
know the most immediate impact of nanotechnology in health care will be seen
in earnest within the next couple of years in the form of medical devices.
It's less complicated to get them developed and through the regulatory
process," says Yoffee.
A plethora of new deals brewed in 2005. Nearly a third (30%) of all
products are being developed as part of collaborations or licensing deals,
another trend similar to the biotechnology industry growth.
But during tough markets, only the top deals attract capital, says Douglas
W. Jamison, president of New York venture capital firm Harris & Harris Group,
Inc. When the market opens up, marginal companies also receive funding -- not
necessarily a positive event for the market but certainly good news for start-
up companies. From a capitalization standpoint, the biggest news during 2005
was the introduction of $20 million series A financings, which allowed
companies to move their technologies into phase II clinical trials, Jamison
says. But without new players coming into the nanobiotech market, the same
investors are putting money into these deals.
Consequently, he expects to see fewer early stage deals in 2006 and a
corresponding weed-out of nanobiotech start-ups.
"This could be the winnowing year for nanobiotech," Jamison says. "The
cream will rise, and others will fail to receive second and third rounds of
funding. In fact, that's already starting to occur."
Industry observers and participants alike can stay on top of the field by
reading NanoBiotech News every week. Every major nanomedicine development --
from both business and scientific perspectives -- is covered in this global
nanobiotechnology intelligence source. The 2006 Nanomedicine, Device &
Diagnostic Report is available for free to NanoBiotech News subscribers. To
order a copy of the report, available for only $199, or to get a free trial
subscription to the newsletter, visit http://www.nanobiotechnews.com or call
(404) 607-9500 or (800) 597-6300.
SOURCE National Health Information, LLC